{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.7","upperLimit":"7.5","value":"6.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"The time from start of study drug to death","dispersionType":"95% Confidence Interval","groups":[{"description":"During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.\n\nCDX-3379 and cetuximab: Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.","id":"OG000","title":"CDX-3379 and Cetuximab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"The time from start of study drug to death from any cause (up to approximately 2 years)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}